Selank and Semax: Nootropic Peptides From Russia

In the landscape of peptide research, few compounds occupy a stranger position than Selank and Semax. Both are approved prescription medications in Russia, available in pharmacies and prescribed by physicians for conditions ranging from generalized anxiety to cognitive impairment after stroke. Both were developed by serious scientists at one of Russia’s most prestigious research institutes. And both remain almost entirely unknown to Western clinical medicine, absent from FDA databases, largely absent from English-language clinical literature, and relegated to the fringes of the nootropics community in North America and Europe.

This disconnect is worth examining carefully. It is not simply a matter of East versus West scientific rivalry. The questions surrounding Selank and Semax touch on fundamental issues in peptide pharmacology: how regulatory standards shape what we consider evidence, how language barriers fragment the global research commons, and how peptides with genuine mechanistic interest can fall through the cracks of conventional drug development.

The Institute of Molecular Genetics: Origins

Both peptides emerged from the Institute of Molecular Genetics (IMG) of the Russian Academy of Sciences in Moscow, under the direction of Nikolai Myasoedov and his colleagues. The research program that produced them began in the late Soviet period, during the 1980s, when Soviet science maintained substantial peptide chemistry capabilities even as the broader economy deteriorated.

The guiding principle behind both compounds was the same: take a naturally occurring regulatory peptide with known biological activity, then modify its structure to improve metabolic stability and bioavailability while retaining or enhancing the desired pharmacological profile. This approach, sometimes called the “regulatory peptide analog” strategy, was a hallmark of Soviet peptide pharmacology and produced several compounds that entered clinical use in Russia but never crossed into Western medicine.

Semax came first, developed in the mid-1980s. Selank followed in the early 1990s. Both were eventually approved by Russian regulatory authorities and manufactured by several Russian pharmaceutical companies for intranasal administration.

Semax: An ACTH Fragment With Nootropic Properties

Structure and Design

Semax has the sequence Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues (Met-Glu-His-Phe) correspond to ACTH(4-7), a fragment of adrenocorticotropic hormone that had been previously identified as carrying the behavioral and cognitive effects of the full ACTH molecule without its hormonal activity. ACTH(4-10) was already known to enhance attention and memory in animal models without stimulating the adrenal cortex, suggesting that the cognitive effects were mediated by central receptors distinct from the classical MC2R pathway.

The IMG team added a Pro-Gly-Pro tripeptide to the C-terminus. This modification was not arbitrary. Pro-Gly-Pro is a fragment of collagen and connective tissue proteins that had independently shown immunomodulatory properties. Attaching it to the ACTH fragment dramatically improved the peptide’s resistance to enzymatic degradation, extending its effective duration of action from minutes to hours. The resulting heptapeptide retained the parent fragment’s cognitive effects while gaining the stability needed for practical clinical use.

Mechanism of Action

Semax’s mechanism of action is not fully elucidated, but several pathways have been identified in preclinical research. The peptide increases brain-derived neurotrophic factor (BDNF) expression in the hippocampus and cortex. A 2006 study by Dolotov and colleagues published in Neuroscience Letters demonstrated that a single intranasal dose of Semax upregulated BDNF mRNA in the rat hippocampus within one hour, an effect that persisted for at least 24 hours. This finding has been replicated by multiple Russian research groups.

Semax also modulates the expression of nerve growth factor (NGF) and glial cell line-derived neurotrophic factor (GDNF), suggesting a broad neurotrophic profile rather than action on a single target. Additionally, the peptide has been shown to inhibit enkephalin-degrading enzymes, which may contribute to its anxiolytic-adjacent effects, and to modulate serotonergic and dopaminergic transmission in the basal ganglia.

The melanocortin receptor involvement is debated. While Semax is structurally derived from ACTH, its binding profile at MC receptors differs substantially from the parent hormone. Some researchers have proposed that Semax acts through melanocortin receptors in the brain (MC4R and possibly MC3R) at concentrations below the threshold for peripheral hormonal effects, while others suggest its primary actions are melanocortin-independent and mediated through neurotrophic factor modulation.

Russian Clinical Data

Semax is approved in Russia under several indications. It is prescribed as a nootropic for cognitive enhancement in healthy individuals, as an adjunct treatment for stroke (both ischemic and hemorrhagic), for cognitive impairment associated with cerebrovascular disease, and for attention deficit disorders in children. The standard formulation is a 0.1% intranasal solution, with a higher-concentration 1% solution (marketed as Semax Forte) used for neurological indications.

The pivotal Russian studies for stroke include a multicenter trial reported by Gusev and Skvortsova in 2001, which enrolled approximately 200 patients with acute ischemic stroke and found that intranasal Semax at 12 mg/day for 5 days improved neurological outcomes at 30 days compared to standard care. The effect was attributed to neuroprotection during the acute phase. A subsequent study by Medvedev and colleagues examined Semax as a cognitive enhancer in patients with chronic cerebrovascular insufficiency, reporting improvements in memory and attention on standardized neuropsychological batteries.

The methodological caveats are significant. Many of these studies were open-label or used small sample sizes. Blinding procedures, when described, were not always rigorous by Western standards. Publication in Russian-language journals means the studies have not been subjected to the same peer review scrutiny as English-language publications in high-impact neuroscience journals. None of this means the results are wrong, but it does mean they require independent replication before Western researchers can confidently build on them.

Selank: A Tuftsin Analog for Anxiety

Structure and Design

Selank has the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four residues (Thr-Lys-Pro-Arg) correspond to tuftsin, a naturally occurring tetrapeptide derived from the Fc region of immunoglobulin G. Tuftsin was first described by Victor Najjar at Tufts University in the 1970s (hence the name) and is known primarily as an immunomodulator that enhances phagocytic activity of macrophages and neutrophils.

The IMG team applied the same stabilization strategy used for Semax: they added the Pro-Gly-Pro C-terminal extension to protect against enzymatic degradation. The resulting heptapeptide retained tuftsin’s immunomodulatory properties while gaining additional anxiolytic effects that were not present in the parent tetrapeptide. This was a genuinely novel finding: the structural modification did not simply stabilize the molecule but appeared to confer new pharmacological activity.

Mechanism of Action

Selank’s anxiolytic mechanism is distinct from benzodiazepines and does not involve direct GABA-A receptor modulation. Instead, the peptide appears to work through several converging pathways. It influences the expression of BDNF, similar to Semax, but with a different regional pattern in the brain. It modulates the balance of interleukin-6 (IL-6), which has emerged as a mediator linking peripheral inflammation to central anxiety responses. And it affects the metabolism of enkephalins by inhibiting the enzymes that degrade these endogenous opioid peptides, effectively prolonging their anxiolytic signaling.

A particularly interesting line of research concerns Selank’s effects on gene expression. A 2009 study by Zozulya and colleagues published in Bulletin of Experimental Biology and Medicine examined the peptide’s effects on the expression of 84 genes involved in inflammatory and immune responses and found significant modulation of several cytokine pathways. A more comprehensive transcriptomic analysis by Seredenin and Voronina, published in 2012, identified changes in the expression of genes involved in GABA neurotransmission, serotonin metabolism, and neurotrophic signaling in the hippocampus of anxious BALB/c mice following Selank administration.

The immunological angle is underappreciated. Unlike most anxiolytics, Selank appears to simultaneously reduce anxiety and enhance immune function, a combination that makes pharmacological sense given the bidirectional relationship between immune activation and anxiety but is unusual in the existing pharmacopeia.

Russian Clinical Data

Selank is approved in Russia for generalized anxiety disorder and neurasthenia, a diagnostic category still used in Russian and Chinese psychiatry that roughly corresponds to chronic fatigue with anxiety and cognitive complaints. The standard formulation is a 0.15% intranasal solution.

The key clinical study, reported by Zozulya and colleagues in 2008, was a randomized controlled trial comparing Selank to medazepam (a benzodiazepine) in patients with generalized anxiety disorder. The trial enrolled 62 patients and found that Selank produced anxiolytic effects comparable to medazepam over a 14-day treatment period, as measured by the Hamilton Anxiety Rating Scale, without the sedation, cognitive impairment, or withdrawal effects associated with the benzodiazepine. A subsequent open-label study examined Selank in patients with anxiety comorbid with organic brain disorders and reported similar anxiolytic efficacy.

The same methodological caveats apply here as with Semax: small sample sizes, limited blinding information in some studies, and publication primarily in Russian-language literature. The comparison to a benzodiazepine rather than a modern first-line anxiolytic (such as an SSRI) also limits the clinical relevance of the findings for Western practice.

Anxiolytic vs. Cognitive Enhancement: Distinct Profiles

While both peptides are sometimes grouped together as “Russian nootropics,” their pharmacological profiles are distinct in important ways. Semax is primarily a cognitive enhancer and neuroprotectant, with its strongest effects observed on attention, working memory, and neurological recovery after acute brain injury. Its anxiolytic effects, while present, are secondary. Selank is primarily an anxiolytic with immunomodulatory properties, and its effects on cognition appear to be mediated largely through anxiety reduction rather than direct cognitive enhancement.

This distinction matters for research design. An investigator studying neuroprotection or neurotrophic factor modulation would find Semax the more relevant compound. An investigator studying the interface between immune function and anxiety would find Selank more appropriate. Conflating the two, as popular nootropic literature often does, obscures important pharmacological differences.

Western Research Gaps

The most striking feature of the Selank and Semax literature is how little of it exists in English-language peer-reviewed journals. A PubMed search for “Semax” returns approximately 150 results, many of which are mechanistic studies in animal models published by Russian groups in journals like Doklady Biological Sciences or Bulletin of Experimental Biology and Medicine. Clinical data is sparse in English. For Selank, the numbers are even smaller.

There is also a structural problem in academic research funding. NIH and European funding agencies are unlikely to prioritize clinical trials of compounds that are already available (unregulated) through peptide suppliers, even if the mechanistic rationale is strong. The paradox is that these peptides’ availability outside conventional channels makes them less likely to receive the rigorous clinical evaluation they need.

What Western Researchers Can Learn

Despite these limitations, the Selank and Semax research programs offer several lessons for the broader peptide field. First, the regulatory peptide analog strategy, taking a known bioactive fragment and modifying it for stability, remains a productive approach to peptide drug design. The Pro-Gly-Pro stabilization motif is a clever piece of medicinal chemistry that deserves wider attention.

Second, the observation that structural modification can confer genuinely new pharmacological activity (as with Selank’s anxiolytic effects emerging from an immunomodulatory parent peptide) suggests that the structure-activity relationships of short peptides are more complex than simple receptor binding models predict. The possibility that peptide fragments may engage multiple signaling systems simultaneously, through mechanisms that do not reduce to single receptor-ligand interactions, is consistent with emerging understanding of peptide pharmacology.

Third, the clinical experience accumulated in Russia, however imperfect by Western standards, constitutes a real-world safety database for intranasal peptide administration that has few equivalents. Semax and Selank have been used by thousands of patients over decades, and the reported adverse event profile is notably benign for both compounds. This does not substitute for controlled trial data, but it does provide a pragmatic safety signal that can inform the design of Western studies.

The story of Selank and Semax is ultimately a story about the fragmentation of global pharmaceutical research. Potentially useful compounds, developed by competent scientists and used clinically in a major country, remain terra incognita for Western medicine because the economic and regulatory structures that connect laboratory discoveries to clinical practice do not operate across this particular border. Whether that gap closes will depend less on the peptides themselves than on the systems we build to evaluate them.

This article is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before making health-related decisions. Clinical trial data referenced here is sourced from peer-reviewed publications and may not reflect the most current findings.